Evidence map›Paper›PMID 34668672›Full record

ArticleThe American journal of managed care2021

340B Drug Pricing Program and hospital provision of uncompensated care.

Sunita M Desai, J Michael McWilliams

Abstract read
In one paragraph

Article in The American journal of managed care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Mapping 340B Funds Flow Through Contract Pharmacies.Inquiry : a journal of medical care organization, provision and financing
    Article
  17. The Association of 340B Program Drug Margins with Covered Entity Characteristics.Inquiry : a journal of medical care organization, provision and financing
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sunita M DesaiDepartment of Population Health, New York University School of Medicine, 227 E 30th St #635, New York, NY 10016. Email: sunita.desai@nyu.edu.
J Michael McWilliams

Funding

PA-20-072, Measuring the Clinical and Economic Outcomes Associated with Delivery Systems: "Are Health Systems Better at Responding to Pandemics?"U19HS024072 · AHRQ · NATIONAL BUREAU OF ECONOMIC RESEARCH · PI CUTLER, DAVID M · 2015 to 2021
$19.8M
Designing policies to incentivize high-quality health care for vulnerable Americans: Evidence from the 340B Drug Pricing ProgramK01HS026980 · AHRQ · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DESAI, SUNITA · 2020 to 2024
$786k
AHRQ HHS K01 HS026980AHRQ HHS U19 HS024072
6 · The paper itself

Abstract

objectivesTo evaluate whether hospital entry into the 340B Drug Pricing Program, which entitles eligible hospitals to discounts on drug purchases and intends for hospitals to use associated savings to devote more resources to the care of low-income populations, is associated with changes in hospital provision of uncompensated care. STUDY

designWe analyzed secondary data on 340B participation and uncompensated care provision among general acute care hospitals and critical access hospitals from 2003 to 2015. We constructed an annual, hospital-level data set on hospital 340B participation from the Office of Pharmacy Information Systems and on uncompensated care provision from the Hospital Cost Reporting Information System.

methodsFocusing on 2 periods of program expansion, we separately analyzed trends in uncompensated care costs for 340B-eligible general acute care hospitals and critical access hospitals, stratified by year of 340B program entry, including a stratum of eligible hospitals that never participated. We used a differences-in-differences approach to quantify whether there were differential changes in provision of uncompensated care after hospitals enter the 340B program relative to hospitals that did not participate or had not yet entered.

resultsWe do not find evidence that hospitals increased provision of uncompensated care after entry into the 340B program differentially more than hospitals that never entered or had not yet entered the program.

conclusionsRelying on hospitals to invest surplus into care for the underserved without marginal incentives to do so or strong oversight may not be an effective strategy to expand safety-net care.

Indexed as

PharmaciesUncompensated CareCosts and Cost AnalysisDrug CostsHospitalsHumans

Identifiers

PMID34668672
PMCPMC8544813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.